Drugs / PF-04620110
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01474941 | Jun → Aug 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01298518 | Feb → May 2011 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01166217 | Jul → Aug 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01146327 | Jun 2010 → Jan 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01064492 | Feb → Mar 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00959426 | Aug 2009 → May 2010 | obesity disorder | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00799006 | Nov 2008 → Jun 2009 | obesity disorder | Pfizer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-04620110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00959426 ↗ |
| Known as | PF-4620110 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1835919 ↗ |
| Action | Inhibit | “Data from 2 Phase I, randomized, double-blind, placebo-controlled trials of the DGAT1i PF-04620110 in healthy participants” PMID 36690550 ↗ Jan 2023 |
| Modality | Small molecule | — CHEMBL1835919 ↗ |
| Route | Oral | “A single oral dose of PF-04620110 will be given.” NCT00799006 ↗ |
| Target | DGAT1 | “Data from 2 Phase I, randomized, double-blind, placebo-controlled trials of the DGAT1i PF-04620110 in healthy participants” PMID 36690550 ↗ Jan 2023 |